Objective. To review the pathophysiology, risk factors, and management of differentiation syndrome (DS) associated with acute promyelocytic leukemia (APL).
Data source. A MEDLINE search was conducted (1977–November 2010) using the terms APL, DS, all-trans retinoic acid (ATRA), retinoic acid syndrome, and arsenic trioxide (ATO).
Methods of study selection. English articles identified from the MEDLINE search were evaluated.
Data extraction and synthesis. With ATRA, ATO, and chemotherapy, a complete remission is achievable for most newly diagnosed APL patients. However, treatment with the differentiating agents, ATRA and ATO, can lead to the development of DS. Signs and symptoms of this syndrome include hyperleukocytosis and cardiorespiratory compromise. Severe complications can develop, if DS is not recognized early and treated promptly with corticosteroids. In addition, patients with a high white blood cell count at diagnosis may benefit from prophylactic steroids.
Conclusions. Early recognition and prompt initiation of corticosteroids are key factors in the management of DS. Healthcare professionals need to be familiar with this complication which can arise from differentiation agents.
LarsonRSTallmanMS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol2003; 16(3): 453–461.
3.
SanzMAGrimwadeDTallmanMS. Management of acute promyelocytic leukemia: recommendation from an expert panel on behalf of the European LeukemiaNet. Blood2009; 113: 1875–1891.
4.
WangZYChenZ. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood2008; 111(5): 2505–2515.
LichtJD. Acute promyelocytic leukemia—weapons of mass differentiation. N Engl J Med2009; 360(9): 928–930.
7.
TallmanMSAltmanJK. How I treat acute promyelocytic leukemia. Blood2009; 114(25): 5126–5135.
8.
De la SernaJMontesinosPVellengaE. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood2008; 111(7): 3395–3402.
9.
Lo-CocoFAmmatunaEMontesinosPSanzMA. Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol2008; 35(4): 401–409.
10.
LuesinkMPenningsJLWissinkWM. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood2009; 114: 5512–5521.
11.
CamachoLHSoignetSLChanelS. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol2000; 18(13): 2620–2625.
12.
EmadiAGoreSD. Arsenic trioxide – an old drug rediscovered. Blood Rev2010; 24(4–5): 191–199.
13.
De BottonSDombretHSanzM. Incidence, clinical features, and outcome of all-trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood1998; 92(8): 2712–2718.
14.
De BottonSChevretSCoiteuxV. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia2003; 17: 339–342.
15.
RustDMSoignetSL. Risk/benefit profile of arsenic trioxide. Oncologist2001; 6(Suppl 2): 29–32.
16.
GuptaVYiQLBrandweinJ. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leuk Res2005; 29(1): 113–114.
17.
FerraraF. Acute promyelocytic leukemia: what are the treatment options?. Expert Opin Pharmacother2010; 11(4): 587–596.
18.
Roche Laboratories, Inc. Vesanoid® (tretinoin) package insert. Nutley, NJ; October 2004.
19.
Cephalon, Inc. Trisenox® (arsenic trioxide) package insert. Frazer, PA; June 2010.
20.
NasrRLallemand-BreitenbachVZhuJGuilleminMCde TheH. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res2009; 15(20): 6321–6326.
21.
NinomiyaMKiyoiHItoMHiroseYItoMNaoeT. Retinoic acid syndrome in NOD/scid mice induced by an acute promyelocytic leukemia cell line. Leukemia2004; 18(3): 442–448.
22.
MontesinosPBerguaJMVellengaE. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood2009; 113: 775–783.
23.
FrankelSREardleyAHellerG. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med1994; 120: 278–286.
24.
JeddiRKacemKBen NejiH. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. Hematology2008; 13(3): 142–146.
25.
JeddiRGhediraHMnifSGouiderEFenauxPMeddebB. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res2010; 34(4): 545–547.
26.
SanzMAMartinGGonzalezM. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood2004; 103(4): 1237–1243.
27.
KelaidiCChevretSDe BottonS. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol2009; 27(16): 2668–2676.
28.
TallmanMSAndersonJWSchifferCA. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood2000; 95(1): 90–95.
29.
TallmanMSAndersenJWSchifferCA. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med1997; 337(15): 1021–1028.
